The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer
Authors:
- Beth AdamsonBABeth Adamson
- Nicholas BrittainNBNicholas Brittain
- Laura WalkerLWLaura Walker
- Ruaridh DuncanRDRuaridh Duncan
- Sara LuzziSLSara Luzzi
- Pasquale RescignoPRPasquale Rescigno
- Suzanne McGillSMSuzanne McGill
- Richard J.S. BurchmoreRBRichard J.S. Burchmore
- Elaine WillmoreEWElaine Willmore
- Ian HicksonIHIan Hickson
- Craig N. RobsonCraig N. Robson
Open Access
- 15 November 2023
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (22)
Abstract
Aberrant androgen receptor (AR) signaling drives prostate cancer (PC), and it is a key therapeutic target. Although initially effective, the generation of alternatively spliced AR variants (AR-Vs) compromises efficacy of treatments. In contrast to full-length AR (AR-FL), AR-Vs constitutively activate androgenic signaling and are refractory to the current repertoire of AR-targeting therapies, which together drive disease progression. There is an unmet clinical need, therefore, to develop more durable PC therapies that can attenuate AR-V function. Exploiting the requirement of coregulatory proteins for AR-V function has the capacity to furnish tractable routes for attenuating persistent oncogenic AR signaling in advanced PC. DNA-PKcs regulates AR-FL transcriptional activity and is upregulated in both early and advanced PC. We hypothesized that DNA-PKcs is critical for AR-V function. Using a proximity biotinylation approach, we demonstrated that the DNA-PK holoenzyme is part of the AR-V7 interactome and is a key regulator of AR-V–mediated transcription and cell growth in models of advanced PC. Crucially, we provide evidence that DNA-PKcs controls global splicing and, via RBMX, regulates the maturation of AR-V and AR-FL transcripts. Ultimately, our data indicate that targeting DNA-PKcs attenuates AR-V signaling and provide evidence that DNA-PKcs blockade is an effective therapeutic option in advanced AR-V–positive patients with PC.Keywords
Funding Information
- JGW Patterson Foundation ((12/21 NU009331))
- Ken Bell Bursary (KBB-01)
- Cancer Research UK (C9380/A25138)
This publication has 65 references indexed in Scilit:
- An androgen receptor N-terminal domain antagonist for treating prostate cancerJournal of Clinical Investigation, 2013
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1Cancer Cell, 2011
- Alternatively spliced androgen receptor variantsEndocrine-Related Cancer, 2011
- Involvement of DNA-dependent Protein Kinase in Normal Cell Cycle Progression through MitosisJournal of Biological Chemistry, 2011
- The secret life of kinases: functions beyond catalysisCell Communication and Signaling, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- The Catalytic Subunit of DNA-Dependent Protein Kinase Regulates Proliferation, Telomere Length, and Genomic Stability in Human Somatic CellsMolecular and Cellular Biology, 2008
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy ResistanceCancer Research, 2008
- GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinaseCell, 1990